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Secondary acute lymphoblastic leukemia is a distinct clinical
entity with prognostic significance
AS Rosenberg1,2, A Brunson1, JK Paulus3, J Tuscano2,4, T Wun1,2,4, THM Keegan1,2 and BA Jonas1,2,4
The effect of prior malignancy on the risk of developing, and prognosis of, acute lymphoblastic leukemia (ALL) is unknown. This
observational study utilized the California Cancer Registry to estimate the risk of developing ALL after a prior malignancy using
standardized incidence ratios (SIRs, 95% confidence intervals). ALL occurring after a malignancy with an SIR41 (increased-risk (IR)
malignancies) was considered secondary ALL (s-ALL). Adjusted hazard ratios (aHRs, 95% confidence intervals) compared the effect
of s-ALL with de novo ALL on overall survival. A total of 14 481 patients with ALL were identified (1988–2012) and 382 (3%) had a
known prior malignancy. Any prior malignancy predisposed patients to developing ALL: SIR 1.62 (1.45–1.79). Hematologic
malignancies (SIR 5.57, 4.38–6.98) and IR-solid tumors (SIR 2.11, 1.73–2.54) increased the risk of developing ALL. s-ALL increased the
risk of death compared with de novo ALL (aHR 1.38 (1.16–1.63)) and this effect was more pronounced among younger patients
(ageo40 years: aHR 4.80 (3.15–7.30); age⩾ 40 years: aHR 1.40 (1.16–1.69)) (interaction Po0.001). This population-based study
demonstrates that s-ALL is a distinct entity that occurs after specific malignancies and carries a poor prognosis compared with de
novo ALL, particularly among patients o40 years of age.
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INTRODUCTION
As cancer survival continues to improve, second primary
malignancies are becoming an increasingly common problem
facing both clinicians and cancer survivors. Acute myelogenous
leukemia evolving from an underlying bone marrow disorder
(secondary acute myelogenous leukemia) or as a result of
radiation or chemotherapy (therapy-related acute myelogenous
leukemia) is well described.1–3 By comparison, little is known
about acute lymphoblastic leukemia (ALL) occurring after an
antecedent malignancy (am-ALL). One large analysis of the
Surveillance, Epidemiology and End Results (SEER) cancer registry
program found that the incidence of ALL was higher than
expected in survivors of Hodgkin lymphoma, small cell lung and
ovarian cancers, and that younger patients were nearly 20 times
more likely to develop ALL than the background population.4 Five
single institution case series,5–9 one leukemia-specific registry,10
four summaries of prior case series11–14 and two SEER-based
studies15,16 have examined ALL patients for a history of prior
malignancy and treatment, and identified prior malignancies
among o1% to 9.6% of ALL patients. Rearrangements of the
MLL gene on chromosome 11 appear more common among ALL
patients with prior malignancies compared with de novo ALL,
supporting the argument that secondary ALL (s-ALL) is a distinct
entity, and may be linked to specific therapies.5–7,14 These s-ALL
cases with MLL and other cytogenetic alterations have been
labeled therapy-related ALL (t-ALL) in many of these
studies.6,7,9,12,13 This line of reasoning has been challenged,
however, by the observed high rates of malignancies within
families of ALL patients with a prior malignancy, leading some to
posit that s-ALL is instead due to constitutional susceptibility to
malignancy.8,10,14
Although studies have described frequencies of prior malig-
nancies among ALL patients,5–8,10,11 no prior study has focused on
the risk of developing ALL among cancer survivors. Furthermore,
the prognostic impact of a prior malignancy on ALL patients is
uncertain.1,2,15,17 Therefore, we utilized data from the population-
based California Cancer Registry (CCR) to determine whether ALL
rates are higher among cancer survivors with specific tumors and
whether ALL in this context confers a worse prognosis. Findings
from this study will have important implications for patients
followed in survivorship clinics and for risk stratification and
treatment of ALL.
MATERIALS AND METHODS
Patients were identified using the CCR database. California state law
mandates that all cancers diagnosed in California are reported to the CCR
since 1 January 1988.18–20 The CCR abstracts high-quality data from
medical records including demographic characteristics (race/ethnicity,
gender, age at diagnosis, marital status, health insurance and neighbor-
hood socioeconomic status), tumor characteristics (primary cancer site,
tumor sequence and stage at diagnosis), initial course of treatment
(chemotherapy, radiation and surgery), vital status and follow-up time.
Vital status and follow-up time were complete through 31 December 2012.
We developed a conceptual framework before analysis that included am-
ALL as a subset of de novo ALL, and that among am-ALL patients some
would have s-ALL and/or t-ALL (Supplementary Figure 1).
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Patient identification
All patients diagnosed with ALL from 1 January 1988 to 31 December 2012
were identified using the SEER site recode for ALL (35 011).21 Tumor
sequence was used to identify first primary ALL (00 or 01) or am-ALL
(401). To ensure the am-ALL diagnosis was a subsequent primary
malignancy, patients with a first primary acute leukemia, chronic
myelogenous leukemia, Burkitt, or lymphoblastic lymphoma or unknown
first primary were excluded from the analyses. Patients with prior chronic
lymphocytic leukemia, chronic myelo-monocytic leukemia and chronic
eosinophilic leukemia were included (n=12). Patients with a latency period
of less than 60 days between their first primary cancer and am-ALL were
excluded.22
Statistical analysis
Categorical data was analyzed using χ2-testing and two-sided P-values
o0.05 were considered statistically significant. Standardized incidence
ratios (SIRs), defined as the ratio of observed number of ALL cases among
cancer survivors to the expected number of de novo ALL in the general
population of California, and corresponding 95% confidence intervals were
calculated to estimate the risk of am-ALL. SEER site recode was utilized to
classify types of cancers.23 Expected numbers of de novo ALL were
calculated by gender, race/ethnicity, 5-year age-categories and 3-year time
periods using first primary ALL rates from the CCR. SIRs were calculated in
strata defined by cancer type and age category, pediatric/adolescent and
young adult (pediatric/AYA, ageo40 years) and older adults (age⩾ 40
years), based on the higher risks of subsequent cancers in younger
compared with older patients.24 Malignancies with statistically significant
SIRs 41 were considered ‘increased risk (IR)’ and ALL developing after an
IR primary was considered s-ALL, as compared with ALL developing after
any am-ALL.
Multivariable cox proportional hazard models were used to compare
survival of am-ALL compared with de novo ALL adjusting for characteristics
at diagnosis, including age, sex, race/ethnicity, marital status, health
insurance, urban residence, neighborhood socioeconomic status and year
of diagnosis. Two primary outcome models included overall survival of (1)
am-ALL vs de novo ALL and (2) s-ALL vs de novo ALL. For deceased patients,
survival time was measured in days from the date of diagnosis to the date
of death from any cause. Patients alive at the study end date (31 December
2012) were censored at this time or at the date of last known contact.
Cross-product interactions of am-ALL and s-ALL with age group were
evaluated in all overall survival models. In all models, the proportional
hazards assumption was assessed using Schoenfeld residuals.25
The CCR records planned first course of treatment including whether
chemotherapy or radiation therapy was employed. Data on specific types
of chemotherapy, doses of chemotherapy or radiation therapy, and areas
of involved treatment are not available in this data set. Therefore, an
exploratory analysis on the effects of initial prior therapy on both the
development, via SIR analysis, and survival, via Cox models, of am-ALL
were performed.
SIRs were calculated in SEER*Stat version 8.3.2 (National Cancer Institute,
Bethesda, MD, USA), all other analysis was performed using SAS Version 9.4
(SAS Institute Inc., Cary, NC, USA). This study was approved by the
Committee for the Protection of Human Subjects of the California and the
University of California, Davis Institutional Review boards.
RESULTS
Patient characteristics
A total of 14 470 patients with ALL were identified. Of these,
14 099 (97%) had de novo ALL and 371 (3%) had am-ALL (Table 1).
Differences in sex, race/ethnicity and neighborhood socioeco-
nomic status were noted between am-ALL and de novo ALL.
Pediatric/AYA cases comprised 78% (n= 11 229) of primary ALL
cases, but these cases represented only 12% (n= 43) of the am-
ALL cohort. The most common prior malignancies were breast
cancer (21%), hematologic malignancies (18%) and male genital
system (15%).
Risk of ALL among cancer survivors
Compared with the background population of California, cancer
survivors had a 62% increase in the incidence of ALL (SIR 1.62
(1.45–1.79)). Hematologic malignancies conferred more than five-
fold IR (SIR 5.57, (4.38–6.98)) and solid tumors conferred a 37% IR
(SIR 1.37 (1.21, 1.53)); however, this risk was driven by specific ‘IR’
solid tumors (Figure 1 and Supplementary Table 1). Although male
and female genitourinary, colorectal and skin cancers were
common antecedent malignancies due to their prevalence in
the background population, they were not associated with IR of
developing ALL. Based on these findings, ALL arising after any IR
malignancy, hematologic or solid was considered s-ALL in
subsequent analyses.
The effect of prior malignancies on the development of s-ALL
was greater in pediatric/AYA than older patients (Figure 1).
Notably, IR solid tumors conferred IR in both age categories, but
the risk was higher among pediatric/AYA (SIR 4.65 (3.09–6.72))
than older (SIR 1.77 (1.40–2.20)) patients. Conversely, among non-
IR solid tumors, the risk of developing ALL was not increased
among older adults (SIR 1.04 (0.89–1.22)), but was over 2.5-fold
higher (SIR 2.57 (1.63–3.86)) in pediatric/AYA patients. This effect
was driven primarily by rectal cancers (n= 3; SIR 22.56 (4.65–
65.93)), which remained non-IR for the entire cohort (n= 9; SIR 1.87
(0.86–3.55)).
Among all cancer survivors, those with prior cancer treatment
had more than twice the incidence of ALL (SIR 2.27 (1.96–2.61)) in
both pediatric/AYA (SIR 5.05 (3.71–6.71)) and older adults (1.93
(1.63–2.26)) (Figure 2). Those with no prior treatment had a small,
but significant increase in ALL incidence (SIR 1.20 (1.03–1.40)) that
was driven by pediatric/AYA patients (SIR 2.27 (1.32–3.63)).
Time from first primary to ALL
The median time from primary malignancy to am-ALL was
67 months (range 2.6–277). The median time from hematologic
malignancy was 68 months (2.6–221) and from IR solid tumors was
69 months (3.8–277). The time from non-IR solid tumors to am-ALL
did not differ greatly (median 64 months (3–269)) (data not
shown).
Survival of secondary ALL
To compare the overall survival of de novo ALL and am-ALL, Cox
proportional models were utilized that accounted for age at
diagnosis, gender, race/ethnicity, era of diagnosis (to account for
changes in treatment and outcome over time) and socioeconomic
status. The hazard of death was increased in am-ALL patients
compared with de novo ALL (adjusted hazard ratio (aHR) 1.19
(1.05–1.34)) (Table 2). However, when taking into account the type
of prior malignancy, the hazard of death remained elevated for
s-ALL patients when compared with de novo ALL (aHR: 1.38 (1.16–
1.63)), whereas there was no difference in the hazard of death
between patients with non-IR solid primary cancers and de novo
ALL. The effect of prior IR solid tumors and prior hematologic
malignancy on survival compared with de novo ALL did not differ
significantly (aHR 1.54 (1.16–2.03) and 1.30 (1.05–1.61), respec-
tively, P for interaction = 0.3449) (data not shown) and therefore
s-ALL was analyzed as a single group.
The effect of s-ALL on survival differed by age (P for interaction
o0.001), with the effect of s-ALL being worse in pediatric/AYA
patients compared with older adults (aHR 4.80 (3.15–7.30) and
1.40 (1.16–1.69), respectively) (Table 2). Unlike pediatric/AYA
patients, older adults with a non-IR prior malignancy also
experienced an increased hazard of death.
In exploratory analysis, cancer survivors with am-ALL who
received either chemotherapy or radiation for their prior cancer
were at significantly IR of death compared to de novo ALL patients
(aHR 1.26 (1.06–1.50)), whereas cancer survivors with am-ALL, who
did not receive chemotherapy or radiation for their prior cancer,
had similar survival to de novo ALL patients (aHR 1.13 (0.96–1.33))
(data not shown).
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Table 1. Patient characteristicsAbbreviations: ALL, acute lymphoblastic leukemia; am-ALL, antecedent malignancy ALL.
Patient characteristics All De novo ALL am-ALL P-value
N % N % N %
All 14 470 100.0% 14 099 100.0% 371 100.0%
Gender
Male 8191 56.6% 8018 56.9% 173 46.6% o0.0001
Female 6279 43.4% 6081 43.1% 198 53.4% o0.0001
Race/ethnicity
Non-Hispanic White 5495 38.0% 5267 37.4% 228 61.5% o0.0001
African American 558 3.9% 542 3.8% 16 4.3% 00.6437
Hispanic 6985 48.3% 6889 48.9% 96 25.9% o0.0001
Asian/Pacific Islander 1280 8.8% 1249 8.9% 31 8.4% 0.7363
Other/unknown 152 1.1% 152 1.1% 0.0444
Age at diagnosis
Age 0–9 6752 46.7% 6746 47.8% 6 1.6% o0.0001
10–19 2663 18.4% 2648 18.8% 15 4.0% o0.0001
20–29 935 6.5% 932 6.6% 3 0.8% o0.0001
30–39 879 6.1% 860 6.1% 19 5.1% 0.4361
40–49 837 5.8% 806 5.7% 31 8.4% 0.0316
50–59 778 5.4% 715 5.1% 63 17.0% o0.0001
60–69 669 4.6% 590 4.2% 79 21.3% o0.0001
70–79 561 3.9% 473 3.4% 88 23.7% o0.0001
80+ 396 2.7% 329 2.3% 67 18.1% o0.0001
Year of diagnosis
1988–1992 2315 16.0% 2301 16.3% 14 3.8% o0.0001
1993–1997 2647 18.3% 2605 18.5% 42 11.3% 0.0004
1998–2002 2838 19.6% 2779 19.7% 59 15.9% 0.0683
2003–2007 3186 22.0% 3078 21.8% 108 29.1% 0.0008
2008–2012 3484 24.1% 3336 23.7% 148 39.9% o0.0001
ALL histology
Precursor cell, B cell 5208 36.0% 5018 35.6% 190 51.2% o0.0001
Precursor cell, NOS 8701 60.1% 8535 60.5% 166 44.7% o0.0001
Precursor cell, T cell 561 3.9% 546 3.9% 15 4.0% 0.8666
Neighborhood socioeconomic status
Low 9528 65.8% 9347 66.3% 181 48.8% o0.0001
High 4786 33.1% 4604 32.7% 182 49.1% o0.0001
Unknown 156 1.1% 148 1.0% 8 2.2% 0.0416
Previous treatment
Chemo or radiation 184 1.3% 184 49.6%
None 14 286 98.7% 187 50.4%
First known tumor
No previous tumor 14099 97.4% 14099 100.0%
Oral cavity/pharynx 7 0.0% 7 1.9%
Digestive system 37 0.3% 37 10.0%
Respiratory system 14 0.1% 14 3.8%
Bone/joints 6 0.0% 6 1.6%
Soft tissue (inc heart) 5 0.0% 5 1.3%
Skin 27 0.2% 27 7.3%
Breast 77 0.5% 77 20.8%
Female genital system 25 0.2% 25 6.7%
Male genital system 57 0.4% 57 15.4%
Urinary system 14 0.1% 14 3.8%
Eye/orbit 2 0.0% 2 0.5%
Brain/other nervous system 7 0.0% 7 1.9%
Endocrine system 15 0.1% 15 4.0%
Lymphoma 40 0.3% 40 10.8%
Myeloma 13 0.1% 13 3.5%
Leukemia 12 0.1% 12 3.2%
Mesothelioma 1 0.0% 1 0.3%
Kaposi sarcoma 2 0.0% 2 0.5%
Misc 10 0.1% 10 2.7%
Secondary ALL




Over the last two decades, several reports on the development of
ALL as a second malignancy have attempted to identify patterns
that could link either prior disease states or prior therapy and ALL
development. To our knowledge, the current study represents the
largest population-based study of de novo compared with am-ALL
Figure 2. SIRs for acute lymphoblastic leukemia preceded by prior chemotherapy/radiation therapy. IR solid tumors defined as those solid
tumors with SIRs41. Prior treatment refers treatment with chemotherapy and/or radiation therapy for the prior malignancy. Older adults are
defined as age ⩾ 40 years and pediatric/AYA are defined as age o40 years. Lower 95% confidence intervals are noted by the whisker.
Figure 1. SIRs for acute lymphoblastic leukemia preceded by prior malignancy. IR solid tumors defined as those solid tumors with SIRs41. Older
adults are defined as age ⩾ 40 years and pediatric/AYA are defined as age o40 years. Lower 95% confidence intervals are noted by the whisker.
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to date and the only study that determined whether a difference
exists in the incidence of ALL in cancer survivors compared with
the general population. The increased SIR for patients with IR
malignancies argues for a link between either therapy6 or an
underlying constitutional predisposition8,10 shared by those
malignancies and ALL.
In the current study, we found that ALL occurs at an increased
rate among a specific subset of solid tumors and hematologic
malignancies. Among pediatric/AYA patients, the effect of ALL
arising as a second malignancy on survival differs depending on
whether it arose after a IR malignancy or not, with a significantly
worse prognosis for s-ALL compared with de novo ALL. In contrast,
in older adults any prior malignancy was associated with an IR of
death. A number of factors may contribute to this latter finding,
including older adult ALL patients having poor baseline survival
rates, making a change in relative survival more difficult to detect,
being less likely to tolerate intensive chemotherapy after having
been treated for any prior malignancy or having more comorbid-
ities especially among cancer survivors. The current study could
not evaluate stem cell transplant utilization or its effect on
survival. Different transplant utilization rates in de novo vs s-ALL
among pediatric/AYA and adult populations may account for
some of the difference observed in the current study and will be
the subject of a future analysis. Taken together, the IR after specific
malignancies coupled with differences in survival, especially
among pediatric/AYA patients, supports the hypothesis that
s-ALL is a distinct entity with prognostic relevance.
The effect of prior malignancy on the survival of ALL has been
reported variously, with three case series published since 2010
reporting median survival times of about 1 year.6–8 Only one of
the reports compared survival of am-ALL with de novo ALL, with
median OS of 12 months compared with 45 months, with a
median follow-up of 24 months. After accounting for baseline
characteristics however, prior malignancy had no effect on
survival. Another report focusing on am-ALL patients undergoing
stem cell transplant found a 4-year overall survival rate of 51%.9
Whether this apparent difference in survival is due to the ability to
undergo stem cell transplant or the effect of the treatment
remains unexplored in the literature. Recently, two large SEER
studies evaluated the prognostic impact of s-ALL and it was
associated with an inferior overall survival compared with de novo
ALL.15,16 However, these studies did not include childreno18 or
consider interactions by age, used a pre-defined subset of prior
malignancies rather than considering all prior malignancies and
did not consider prior therapy in their analyses. Importantly, these
studies did not report SIRs for the prior malignancies used in their
analyses and it is not clear whether they considered the possibility
that some am-ALL cases may reflect de novo ALL.
Aberrations in the MLL gene, most commonly t(4;11),5–10
hypodiploidy6 and the presence of t(9;22)7–10 are frequent
findings in am-ALL. In two reports comparing patient character-
istics of am-ALL patients who had, or had not, received prior
chemotherapy or radiation, 88% (n= 7)(6) and 100% (n= 2)(8) of
patients with t(4;11) had prior therapy, whereas 44% (n= 7)(6) and
67% (n= 8)(8) patients with the t(9;22) had prior therapy,
suggesting an association between both cytogenetic defects
and prior therapy. Accordingly, these and other studies have
concluded that cases of am-ALL following prior chemotherapy/
radiation are best characterized as t-ALL. In our exploratory
analysis considering treatment of a prior malignancy, both
chemotherapy and radiation were associated with a higher
incidence of ALL among cancer survivors and higher risk of death
after am-ALL. The differences between the SIRs in our primary
analysis and the exploratory analysis considering prior treatment
suggest distinct s-ALL and t-ALL subpopulations probably exist in
addition to an overlapping subpopulation of s-ALL and t-ALL.
Taken in sum, the current study supports the hypothesis that am-
ALL is a heterogeneous subset of ALL comprising s-ALL, which
occurs as a result of an underlying predisposition, either
constitutional or disease-related,8,10 t-ALL, which occurs as a
result of chemotherapy/radiation in IR and some non-IR prior
malignancies, and ALL arising after non-IR malignancies, which
may be more akin to de novo ALL.
This study of the CCR has limitations. It does not contain
cytogenetic or molecular data. The survival analyses may be
subject to index event bias.26 Although this type of bias is
unpredictable in its direction and effect, we anticipate it would
bias the survival analysis away from statistical significance.
Treatment data in the CCR likely under-ascertains full-course of
therapy. Thus, analyses based on treatment were considered
exploratory and should be interpreted with some caution, as it is
likely that a proportion of patients recorded as not receiving initial
treatment, in fact did. However, under-ascertainment of treatment
is more likely to bias our results towards the conclusion that there
is no difference in risk of developing ALL or in survival between
those patients receiving prior treatment and those who did not.
Therefore, both the SIR and survival data presented is likely to
underestimate the true effect of IR-malignancies on the develop-
ment of s-ALL and of s-ALL on survival. Taken in sum, we present
evidence for s-ALL and t-ALL in agreement with prior reports.6,7
Table 2. Effect of prior malignancy on hazard of death from all causes among ALL patients by age group, California, 1988–2012
Model Variable aHR 95% CI P-value
A de novo ALL REF
am-ALLa 1.19 (1.05, 1.34) 0.0062
B de novo ALL REF
s-ALLb 1.38 (1.16, 1.63) 0.0003
Prior non-IR solid tumorsc 1.05 (0.89, 1.24) 0.5536
C s-ALLb (vs de novo ALL)
Ageo40 years 4.80 (3.15, 7.30) o .0001
Age⩾ 40 years 1.40 (1.16, 1.69) 0.0004
Prior non-IR solid tumorsc (vs de novo ALL)
Ageo40 years 1.34 (0.34, 5.37) 0.6781
Age⩾ 40 years 1.54 (1.31, 1.81) o .0001
Abbreviations: CI, confidence interval; aHR, adjusted hazard ratio of death; ALL, acute lymphoblastic leukemia; am-ALL, antecedent malignancy ALL; IR,
increased risk; s-ALL, secondary ALL. All models accounting for sex, race/ethnicity, age at diagnosis, marital status, year of diagnosis, histology (B-cell, T-cell and
not-otherwise-specified), neighborhood socioeconomic status, rural (vs urban) location. aam-ALL is defined as ALL after any prior malignancy. bs-ALL is defined
as ALL occurring after IR malignancies (hematologic malignancies and salivary gland, bone and joint, breast, testis, brain, thyroid and other endocrine
including thymus cancers). cNon-IR solid tumors were all malignancies not associated with an increased risk of developing ALL as a second malignancy.
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There are also a number of strengths in the population-based
data source. The CCR includes >99% of all invasive cancers
diagnosed in the state of California. California has a large,
socioeconomically and racial/ethnically diverse population, and
includes patients treated in academic and community settings, thus
making these results more generalizable than prior studies. This is
the first study to comprehensively consider the effect of all prior
malignancies on the incidence of ALL, and the largest study, to date,
to compare overall survival of patients with de novo and s-ALL.
In conclusion, s-ALL is a distinct entity from de novo ALL and
carries adverse prognostic implications that vary by age. Secondary
ALL is of particular relevance in the pediatric/AYA population, in
whom ALL would be otherwise quite treatable with a high rate of
cure. Furthermore, the existence of t-ALL as a distinct subtype of
ALL, sharing overlap with s-ALL, is suggested by this study. Further
exploration of the potential relationship with specific chemother-
apeutic and radiation regimens is both warranted and necessary to
understand the genetic and molecular underpinnings s-ALL.
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